Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2018 Jan;20(1):3-15.
doi: 10.1007/s12094-017-1790-3. Epub 2017 Nov 9.

SEOM clinical guideline of diagnosis and management of low-grade glioma (2017)

J M Sepúlveda-Sánchez  1 , J Muñoz Langa  2 , M Á Arráez  3 , J Fuster  4 , A Hernández Laín  5 , G Reynés  2 , V Rodríguez González  6 , E Vicente  7 , M Vidal Denis  8 , Ó Gallego  9
Affiliations
Practice Guideline

SEOM clinical guideline of diagnosis and management of low-grade glioma (2017)

J M Sepúlveda-Sánchez et al. Clin Transl Oncol. 2018 Jan.

Erratum in

Abstract

Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas, and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed. The 2016 World Health Organization (WHO) classification has updated the definition of these tumors to include their molecular characterization, including the presence of isocitrate dehydrogenase (IDH) mutation and 1p/19p codeletion. In this new classification, the histologic subtype of grade II-mixed oligoastrocytoma has also been eliminated. The precise optimal management of patients with low-grade glioma after resection remains to be determined. The risk-benefit ratio of adjuvant treatment must be weighed for each individual.

Keywords: Astrocytoma; Guideline; Low-grade glioma; Neurooncology; Oligodendroglioma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Figures

Fig. 1
Fig. 1
*It is recommended to start with immunochemistry for R132H-mutant IDH1 followed by IDH1 and IDH2 sequencing of the tumors that were negative for R132H-mutant IDH1 by immunochemistry. **Characteristic but not necessary for diagnosis. ***Recommended to confirm the astrocytic subtype but not necessary for diagnosis. Usually performed with immunochemistry. ****Characteristic but not necessary for diagnosis
Fig. 2
Fig. 2
Diffuse grade 2 astrocytoma: Left parietal mass with low T1 signal and high and heterogenious T2 signal with cystic areas withoyt contrast enhancement. Sagital T1 sequence (a), Axial T2 (b) and T1 postcontrast sequence (c). Perfussion MRI shows no elevation of rCBV (d). MRI spectroscopy: low NAA peak without lactate peak (e). Post process DTI (tractography): Left piramidal tracts displacement (f)
Fig. 3
Fig. 3
Therapeutic algorithm for difuse low-grade gliomas
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dykewicz CA. Centers for Disease Control and Prevention (U.S.), Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33:139–144. doi: 10.1086/321805. - DOI - PubMed
    1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–820. doi: 10.1007/s00401-016-1545-1. - DOI - PubMed
    1. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129(1):133–146. doi: 10.1007/s00401-014-1370-3. - DOI - PubMed
    1. Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas. Acta Neuropathol. 2015;129(4):585–596. doi: 10.1007/s00401-015-1398-z. - DOI - PMC - PubMed
    1. Atlas S. Magnetic resonance imaging of the brain and spine. 3. Philadelphia: Lippincott Williams & Wilkins; 2004.

Publication types